Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

BACKGROUND: Management of multi-drug-resistant (MDR) HIV-1 remains a challenge. The advent of antiretroviral (ARVs) with novel mechanisms of action are needed to expand therapeutic options for MDR patients. Ibalizumab (IBA) is a humanized monoclonal antibody with a unique binding specificity to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Emu, Brinda, Fessel, W Jeffery, Schrader, Shannon, Kumar, Princy N, Richmond, Gary, Win, Sandra, Weinheimer, Steven, Marsolais, Christian, Lewis, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632088/
http://dx.doi.org/10.1093/ofid/ofx162.093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632088/
http://dx.doi.org/10.1093/ofid/ofx162.093

Ejemplares similares